大剂量左氧氟沙星治疗慢性阻塞性肺疾病急性加重期临床效果及降低早期再发风险的研究

doi:10.19739/j.cnki.issn1001-9510.2019.05.003

Abstract
Figure/Table
References
Related Citation (0)

Download: PDF (963 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the clinical effect and risk of early recurrence risk of high dose levofloxacin on the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods 92 patients with acute exacerbation of COPD were randomly divided into observation group and control group. The observation group was given levofloxacin 750 mg qd 5 days, while the control group was given levofloxacin 500 mg qd 10 days. Clinical effects between the two groups after treatment and 8 weeks after treatment were compared. Results There was no significant difference of the initial clinical success rate between the observation group and the control group. The use of antimicrobial agents and the duration of hospitalization of the observation group were shorter than those of the control group. The pathogen clearance rate of the observation group was higher than that of the control group. The rate of re-acute exacerbation of the observation group was lower than that of the control group within 8 weeks after treatment. There was no significant difference of pulmonary function at 8 weeks after treatment, and the CAT score of the observation group was better than that of the control group. No serious drug-related adverse reactions were found in the study. Conclusion Compared with routine therapy, the high dose levofloxacin has good initial clinical success rate, higher pathogen clearance rate, lower risk of early acute exacerbation and better improvement of clinical symptoms.

Key words： levofloxacin chronic obstructive pulmonary disease clinical effect recurrence ring

Received: 08 May 2019

PACS:

R562.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Xueping
	WANG Meng
	HOU Xinfeng
	HE Dandan
	LI Xin
	ZHAI Yunqing

Cite this article:

ZHANG Xueping,WANG Meng,HOU Xinfeng, et al. Clinical effect and risk of early recurrence of high dose levofloxacin on the treatment of acute exacerbation of chronic obstructive pulmonary disease[J]. 滨州医学院学报, 2019, 42(5): 328-331.

URL:

http://manu58.magtech.com.cn/Jwk_bzyxy/EN/10.19739/j.cnki.issn1001-9510.2019.05.003 OR http://manu58.magtech.com.cn/Jwk_bzyxy/EN/Y2019/V42/I5/328

[1] Elixhauser A, Au D H, Podulka J. Readmissions for Chronic Obstructive Pulmonary Disease, 2008[J]. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs:#121.
[2] Aaron S D, Vandemheen K L, Hebert P, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease[J]. N Engl J Med, 2003, 348(26): 2618-2625.
[3] Torres A, Liapikou A. Levofloxacin for the treatment of respiratory tract infections [J]. Expert Opin Pharmacother, 2012, 13(8):1203-1212.
[4] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013年修订版)[J]. 中华结核和呼吸杂志, 2013, 36(4): 255-264.
[5] Zhao T, Chen L A, Wang P, et al. A randomized,open,multicenter clinical study on the short course of intravenous infusion of 750 mg of levofloxacin and the sequential standard course of intravenous infusion/oral administration of 500 mg of levofloxacin for treatment of community-acquired pneumonia[J]. J Thorac Dis, 2016, 8(9):2473-2484.
[6] Wilson R, Anzueto A, Miravitlles M, et al. A novel study design for antibiotic trials in acute exacerbations of COPD:MAESTRAL methodology[J]. Int J Chron Obstruct Pulmon Dis, 2011, 6:373-383.
[7] Mantero M, Rogliani P, Di Pasquale M, et al. Acute exacerbations of COPD:risk factors for failure and relapse[J]. Int J Chron Obstruct Pulmon Dis, 2017,12:2687-2693.
[8] Sethi S, Murphy T F. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state of the art review[J]. Clin Microbiol Rev, 2001, 14: 336-363.
[9] 石宝平, 钱叶长, 王丽华, 等. 慢性阻塞性肺疾病急性加重期患者病原体检测分析[J].山东医药, 2010, 50(15): 8-20.
[10] Felmingham D, Grüneberg R N. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections[J]. J Antimicrob Chemother, 2000, 45(2):191-203.
[11] Dvoretskiǐ L I, Dubrovskaia N V, Grudinina S A, et al. Levofloxacin and macrolides in chronic bronchitis exacerbation:comparative analysis of the treatment efficacy and nonrelapsing periods[J]. Antibiot Khimioter, 2007, 52(7-8):21-31.[12] Nicolau D P, Sutherland C, Winget D, et al. Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis [J]. Pulm Pharmacol Ther, 2012, 25(1):94-98.
[13] Lister P D. Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae [J]. Diagn Microbiol Infect Dis, 2002, 44:43-49.
[14] Frei C R, Burgess D S. Pharmacodynamic analysis of ceftriaxone,gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation [J]. Pharmacotherapy, 2005, 25:1161-1167.
[15] Wedzicha J A, Seemungal T A. COPD exacerbations:defining their cause and prevention [J]. Lancet, 2007, 370(9589): 786-796.
[16] Cabrera-Rubio R, Garcia-Núñez M, Setó L, et al. Microbiome diversity in the bronchial tracts of patients with chronic obstructive pulmonary disease[J]. J Clin Microbiol, 2012, 50(11):3562-3568.
[17] Patel I, Seemungal T, Wilks M, et al. Relationship between bacterial colonisation and the frequency,character,and severity of COPD exacerbations [J]. Thorax, 2002, 57(9): 759-764.
[18] Wilson R, Allegra L, Huchon G, et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis[J]. Chest, 2004, 125(3):953-964.
[19] Khashab M M, Xiang J, Kahn J B. Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections[J]. Curr Med Res Opin, 2006, 22(10):1997-2006.